跳至主要内容
临床试验/ACTRN12621000228886
ACTRN12621000228886已完成未知

A randomized placebo-controlled pilot trial on palmitoylethanalomide and curcumin for pain management in patients with chronic pain

Integria Healthcare (Australia) Pty Ltd.0 个研究点目标入组 45 人开始时间: 2021年3月4日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
45

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 75 Years(—)
性别
All

入选标准

  • Participants meeting the following criteria to be included in the study:
  • - Adults with chronic pain – defined as persistent pain for 12 weeks or more.
  • - Average pain score of 4 or >4 on the visual analogue scale (0-10) for related pain intensity in 3-day diary.

排除标准

  • Participants meeting the following criteria to be excluded from the study:
  • - Diagnosed with any of the following medical conditions: neurological disease, gallstones or bile duct obstruction, cancer, currently unwell with acute infection or fever.
  • - Cause of chronic pain is related to a hormonal condition such as menstrual pain or endometriosis, or is autoimmune in nature.
  • - Currently experiencing acute pain unrelated to chronic pain.
  • - In poor general health or baseline blood tests shows abnormal results that require further investigation (as evaluated by PI).
  • - Taking any of the following medications: anti-platelet or anti-coagulant medication, steroids, turmeric or curcumin or PEA supplements, within previous four weeks.
  • - Taking any herbal or nutritional supplements, unless consistently taking for four weeks or more and planning to continue with them throughout the study. Patients with inconsistent use may choose to stop taking the supplements and be re-evaluated for study entry after one week.
  • - Pregnancy, planned pregnancy, or currently breastfeeding.
  • - Planned surgery within two months.
  • - Allergy/sensitivity to study drugs or their formulations.
  • - Individuals that have participated in another clinical trial in the last 30 days.
  • - Inability or unwillingness of subject or legally acceptable representative to give written informed consent.

研究者

相似试验